PubRank

Naoki Yajima

Author PubWeight™ 19.49‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res 2005 1.76
2 Expression level of ECT2 proto-oncogene correlates with prognosis in glioma patients. Oncol Rep 2006 1.19
3 Gene expression signature-based prognostic risk score in patients with glioblastoma. Cancer Sci 2013 0.93
4 Dendritic cell-based glioma immunotherapy (review). Int J Oncol 2003 0.92
5 Interactive presurgical simulation applying advanced 3D imaging and modeling techniques for skull base and deep tumors. J Neurosurg 2013 0.90
6 Induction of autophagy in temozolomide treated malignant gliomas. Neuropathology 2011 0.90
7 Marked enhancement of antitumor immune responses in mouse brain tumor models by genetically modified dendritic cells producing Semliki Forest virus-mediated interleukin-12. J Neurosurg 2002 0.89
8 Tumor mRNA-loaded dendritic cells elicit tumor-specific CD8(+) cytotoxic T cells in patients with malignant glioma. Cancer Immunol Immunother 2003 0.86
9 Increased expression of CCAAT/enhancer binding protein beta correlates with prognosis in glioma patients. Oncol Rep 2006 0.86
10 Gene expression signature-based prognostic risk score in patients with primary central nervous system lymphoma. Clin Cancer Res 2012 0.84
11 Induction of an antitumor immunological response by an intratumoral injection of dendritic cells pulsed with genetically engineered Semliki Forest virus to produce interleukin-18 combined with the systemic administration of interleukin-12. J Neurosurg 2003 0.84
12 Deterioration after surgical treatment of spinal dural arteriovenous fistula associated with spinal perimedullary fistula. Neurol Med Chir (Tokyo) 2012 0.83
13 Identification and validation of a gene expression signature that predicts outcome in malignant glioma patients. Int J Oncol 2011 0.81
14 Interactive virtual simulation using a 3D computer graphics model for microvascular decompression surgery. J Neurosurg 2012 0.81
15 Administration of interleukin-12 and -18 enhancing the antitumor immunity of genetically modified dendritic cells that had been pulsed with Semliki forest virus-mediated tumor complementary DNA. J Neurosurg 2002 0.81
16 Results of treatment of 112 cases of primary CNS lymphoma. Jpn J Clin Oncol 2008 0.81
17 Tumor lysate and IL-18 loaded dendritic cells elicits Th1 response, tumor-specific CD8+ cytotoxic T cells in patients with malignant glioma. J Neurooncol 2005 0.80
18 Salvage therapy and late neurotoxicity in patients with recurrent primary CNS lymphoma treated with a modified ProMACE-MOPP hybrid regimen. Leuk Lymphoma 2007 0.79
19 Immuno-chemotherapy with a combination of rituximab, methotrexate, pirarubicin and procarbazine for patients with primary CNS lymphoma--a preliminary report. Leuk Lymphoma 2007 0.77
20 Isolation and characterization of an N-linked oligosaccharide that is increased in glioblastoma tissue and cell lines. Int J Oncol 2005 0.76
21 [Long-term results of decompressive surgery without fusion for degenerative spondylolisthesis]. No Shinkei Geka 2014 0.76
22 Novel devices for intraoperative monitoring of glossopharyngeal and vagus nerves during skull base surgery. Surg Neurol Int 2013 0.75
23 Salvage immuno-chemotherapy with a combination of rituximab, high-dose cytarabine, mitoxantrone and dexamethasone for patients with primary CNS lymphoma: a preliminary study. Leuk Lymphoma 2007 0.75
24 [Dendritic cell therapy for malignant glioma]. No To Shinkei 2003 0.75
25 [Long-term Results Regarding the Instability of Decompressive Surgery without Fusion for Degenerative Spondylolisthesis]. No Shinkei Geka 2015 0.75
26 Selection of surrogate marker genes in primary central nervous system lymphomas for radio-chemotherapy by DNA array analysis of gene expression profiles. Int J Oncol 2003 0.75
27 Hematoma in the splenium of the corpus callosum in the subacute stage of subarachnoid hemorrhage--three case reports. Neurol Med Chir (Tokyo) 2010 0.75